Shots:

• The approval is based on P-III MEDALIST study involves assessing ReblozyL vs PBO in a ratio (2:1) in adult patients with very low- to intermediate-risk MDS-RS requiring regular RBC transfusions (>2 RBC units/ 8 wks)
• The results showed transfusion independence for 8 wks or longer during the first 24 wks (38% vs. 13%)
• Reblozyl (luspatercept) is the 1^st and only erythroid maturation agent approved in the US- EU and Canada for the treatment of anemia in certain blood disorders and helps to regulate late-stage RBC maturation to potentially reduce the need for RBC transfusions

 ­ Ref: Acceleron | Image: BMS